UPTRAVI® (selexipag)—The Only Oral PAH Therapy Targeting the Prostacyclin Pathway Proven to Delay Disease Progression1

PRIMARY ENDPOINT: TIME TO FIRST DISEASE PROGRESSION EVENT IN THE GRIPHON TRIAL1

UPTRAVI vs Placebo Primary Endpoint Graph

GRIPHON Trial Primary Endpoint Events Up to the End of Treatment

UPTRAVI Reductions in Hospitalizations versus Placebo Treatment Effects


Reductions in PAH-related hospitalization and other disease progression events drove an overall 40% risk reduction

PAH BACKGROUND THERAPY AT BASELINE

UPTRAVI Treatment Effect Taken Alone Versus Combined

The treatment effect of UPTRAVI on time to first PAH disease progression event was consistent irrespective of PAH background therapy

Median duration of exposure to UPTRAVI was 1.4 years.

Disease progression included: death, hospitalization for PAH, PAH worsening resulting in need for lung transplantation or balloon atrial septostomy, initiation of parenteral prostanoid therapy or chronic oxygen therapy, or other disease progression based on a 15% decrease from baseline in 6MWD plus worsening of Functional Class or need for additional PAH-specific therapy.